Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura
There is limited data on the use of caplacizumab beyond the initial treatment course. We describe a patient case demonstrating the efficacy of a second course of caplacizumab in a patient with relapsed acquired thrombotic thrombocytopenic purpura (TTP). A 25-year-old female was treated for an initia...
Main Authors: | Jon Shaffer, Angela Grove |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-07-01
|
Series: | Platelets |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09537104.2021.1981851 |
Similar Items
-
Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience
by: Brandon Tse, et al.
Published: (2023-12-01) -
Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
by: Constantine N. Logothetis, et al.
Published: (2021-07-01) -
Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
by: Rodgers GM, et al.
Published: (2023-03-01) -
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
by: Eleni Gavriilaki, et al.
Published: (2023-10-01) -
Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a normal platelet count during treatment with caplacizumab
by: Kim Ditzel, et al.
Published: (2022-04-01)